Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 7/20 | 1.00 |
| ▸ | MGLL | Q99685 | 6/20 | 0.68 |
| ▸ | FAAH | O00519 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8779419 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL7785894 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43882 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL1574552 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43969 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779453 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL24939859 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL3291535 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6940132 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779402 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5475021-A | Administering N-substituted succinimides | VANDERBILT UNIVERSITY (US) | 1995-12-12 | — | — | US | claimed |
| WO-1995015163-A1 | NOVEL COMPOUNDS FOR INHIBITION OF CYCLOOXYGENASE ACTIVITY | VANDERBILT UNIVERSITY (US) | 1995-06-08 | — | — | WO | claimed |
| US-12408914-B2 | Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials | CILAG GMBH INTERNATIONAL (CH) | 2025-09-09 | — | — | US | disclosed |
| EP-4543502-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | Cilag GmbH International (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240423617-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024261659-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | WO | disclosed |
| US-20240423620-A1 | COMPRESSIBLE SURGICAL ADJUNCTS, CARTRIDGES, AND CARTRIDGE ASSEMBLIES AND METHODS OF MAKING SURGICAL ADJUNCTS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240382613-A1 | METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES | THE PENN STATE RESEARCH FOUNDATION | 2024-11-21 | — | — | US | disclosed |
| EP-4447944-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240335540-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | PENN STATE RES FOUND (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118613287-A | Compositions and methods for targeted delivery of therapeutic and/or diagnostic substances | 宾夕法尼亚州立大学研究基金会 | 2024-09-06 | — | — | CN | disclosed |
| US-20230022129-A1 | RESIST MATERIAL AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022226100-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | SEAGEN INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-110498993-A | A kind of porous PVA/Cellulose nanocrystal hydrogel and preparation method thereof | CHANGCHUN INST APPLIED CHEMISTRY CAS | 2019-11-26 | — | — | CN | disclosed |
| CN-110028781-A | A kind of selfreparing aqueous polyurethane/Cellulose nanocrystal composite material and preparation method | 中国科学院长春应用化学研究所 | 2019-07-19 | — | — | CN | disclosed |
| EP-1016659-B1 | Bismaleimides comprising mesogenic groups and oligomeric liquid crystalline bismaleimides | DAINIPPON INK & CHEMICALS (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6169186-B1 | LIQUID CRYSTALS AND LIQUID CRYSTALLINE POLYMERS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-1016659-A1 | Bismaleimides comprising mesogenic groups and oligomeric liquid crystalline bismaleimides | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-5475021-A | Administering N-substituted succinimides | VANDERBILT UNIVERSITY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995015163-A1 | NOVEL COMPOUNDS FOR INHIBITION OF CYCLOOXYGENASE ACTIVITY | VANDERBILT UNIVERSITY (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382613-A1 | METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES | PAICS, APEX1, ADM2 | PTGS1 954/4885PTGS2 837/4885MGLL 2329/4885 |
| US-20240335540-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | PAICS, CD47, CA13 | PTGS1 2128/4885PTGS2 1937/4885MGLL 3468/4885 |
| US-20230022129-A1 | RESIST MATERIAL AND PATTERNING PROCESS | GFER, LBR, PCNA | PTGS1 3908/4885PTGS2 3014/4885MGLL 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.